CC

Chemours Co

Add to Watchlist

Advanced Chart

13.880

-0.29(-2.047%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

14.180

Open

14.170

VWAP

Vol

2.91M

Mkt Cap

2.08B

Low

13.5701

Amount

EV/EBITDA(TTM)

7.71

Total Shares

148.90M

5.76B

EV/OCF(TTM)

P/S(TTM)

0.37

The Chemours Company provides industrial and specialty chemical products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. The Company’s segments include Titanium Technologies, Thermal & Specialized Solutions and Advanced Performance Materials. The Titanium Technologies segment is a provider of titanium dioxide pigment, a premium white pigment used to deliver whiteness, brightness, opacity and protection in various applications. The Thermal & Specialized Solutions segment is a provider of refrigerants, thermal management solutions, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment is a provider of high-end polymers and advanced materials. Its flagship products include brands such as Opteon, Freon, Ti-Pure, Nafion, Teflon, Viton, and Krytox. The Company serves over 2,700 customers in approximately 110 countries.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

1.57B

+1.87%

0.457

+20.25%

1.54B

+2.72%

0.495

+23.7%

1.41B

+4.11%

0.376

+241.42%

Estimates Revision

The market is revising Upward the revenue expectations for The Chemours Company (CC) for FY2025, with the revenue forecasts being adjusted by 0.41% over the past three months. During the same period, the stock price has changed by 12.48%.

Revenue Estimates for FY2025

Revise Upward

+0.41%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-19.31%

In Past 3 Month

Stock Price

Go Up

+12.48%

In Past 3 Month

11 Analyst Rating

11.02% Upside

Wall Street analysts forecast CC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CC is 15.41 USD with a low forecast of 11.50 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

5 Hold

0 Sell

Moderate Buy

11.02% Upside

Current: 13.880

Low

11.50

Averages

15.41

High

20.00

11.02% Upside

Current: 13.880

Low

11.50

Averages

15.41

High

20.00

Mizuho

Outperform

maintain

$13 -> $16

2025-07-15

Reason

Mizuho

Price Target

$13 -> $16

2025-07-15

maintain

Outperform

Reason

Mizuho raised the firm's price target on Chemours to $16 from $13 and keeps an Outperform rating on the shares. The firm updated price targets in chemicals and packaging ahead of the Q2 reports. It says the new targets reflect the recent market multiple recovery. Mizuho's top picks are all specialty and defensive names: Corteva (CTVA), Crown (CCK) and Linde (LIN). A pause in tariffs likely pulled forward some demand, which could create a year-end slowdown, the analyst tells investors in a research note.

RBC Capital

Outperform

maintain

$14 -> $15

2025-07-03

Reason

RBC Capital

Price Target

$14 -> $15

2025-07-03

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Chemours to $15 from $14 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 results among select Chemicals names. Recent conversations with investor relations teams have generally shown that demand has remained somewhat tepid through Q2, while Building and Construction activity has been somewhat muted, the analyst tells investors in a research note. The ongoing tariff uncertainty has weighed on export markets, which has resulted in North America polyurethane markets being backed up, with continued price pressure expected in the near-term, and Durables demand has yet to see a material recovery, RBC added.

Barclays

Equal Weight

downgrade

$16 -> $13

2025-05-28

Reason

Barclays

Price Target

$16 -> $13

2025-05-28

downgrade

Equal Weight

Reason

Barclays lowered the firm's price target on Chemours to $13 from $16 and keeps an Equal Weight rating on the shares. The firm updated estimates and price targets for SMID-cap chemical companies post the Q1 reports.

Morgan Stanley

analyst

Equal Weight

downgrade

$22 -> $15

2025-05-12

Reason

Morgan Stanley

analyst

Price Target

$22 -> $15

2025-05-12

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Chemours to $15 from $22 and keeps an Equal Weight rating on the shares. Commentary indicates that though domestic demand remained at average levels in April, a reduction of polyethylene exports drove increased market length, notes the analyst, who adds that expectations for lower prices are likely a product of a reported market imbalance in export markets due to buyers in China, Europe and Latin America limiting orders.

Truist Securities

Peter Osterland

Strong Buy

Maintains

$27 → $22

2025-04-14

Reason

Truist Securities

Peter Osterland

Price Target

$27 → $22

2025-04-14

Maintains

Strong Buy

Reason

Barclays

Michael Leithead

Hold

Maintains

$19 → $16

2025-04-01

Reason

Barclays

Michael Leithead

Price Target

$19 → $16

2025-04-01

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Chemours Co (CC.N) is 8.28, compared to its 5-year average forward P/E of 9.37. For a more detailed relative valuation and DCF analysis to assess Chemours Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

9.37

Current PE

8.28

Overvalued PE

12.91

Undervalued PE

5.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

6.77

Current EV/EBITDA

6.98

Overvalued EV/EBITDA

7.82

Undervalued EV/EBITDA

5.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

0.68

Current PS

0.35

Overvalued PS

0.85

Undervalued PS

0.52

Financials

Annual

Quarterly

FY2025Q1

YoY :

+1.33%

1.37B

Total Revenue

FY2025Q1

YoY :

-27.12%

86.00M

Operating Profit

FY2025Q1

YoY :

-107.69%

-4.00M

Net Income after Tax

FY2025Q1

YoY :

-108.57%

-0.03

EPS - Diluted

FY2025Q1

YoY :

-50.00%

-196.00M

Free Cash Flow

FY2025Q1

YoY :

-19.13%

17.25

Gross Profit Margin - %

FY2025Q1

YoY :

-9260.00%

-13.74

FCF Margin - %

FY2025Q1

YoY :

-107.53%

-0.29

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 301.18% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

154.8K

USD

0-12

Months

0.0

USD

Bought

0-3

251.6K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

1.2M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

380.5K

Volume

Months

6-9

340.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 301.18% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

154.8K

USD

0-12

Months

0.0

USD

Bought

0-3

251.6K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CC News & Events

Events Timeline

2025-07-08 (ET)

2025-07-08

11:02:34

Chemical stocks on the rise after new use rules withdrawn by EPA

2025-06-19 (ET)

2025-06-19

07:43:27

Chemours pre-announcement has 'more positives than negatives,' says BMO Capital

2025-06-18 (ET)

2025-06-18

06:48:48

Chemours sees Q2 adjusted EBITDA $215M-$225M

News

4.5

07-09NASDAQ.COM

Stocks Finish Mixed on Strength in Chip Makers and Higher Bond Yields

7.0

07-08SeekingAlpha

Chemours surges to highest since March as EPA pulls plan to rewrite asbestos phaseout rule

2.0

07-08Benzinga

Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket

People Also Watch

PRKS

United Parks & Resorts Inc

Simmons First National Corp

Twist Bioscience Corp

Independent Bank Corp (Massachusetts)

65.870

USD

-0.56%

FAQ

What is Chemours Co (CC) stock price today?

The current price of CC is 13.88 USD — it has decreased -2.05 % in the last trading day.

CC

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CC News & Events

Events Timeline

News

People Also Watch

FAQ

What is Chemours Co (CC) stock price today?

What is Chemours Co (CC)'s business?

What is the price predicton of CC Stock?

What is Chemours Co (CC)'s revenue for the last quarter?

What is Chemours Co (CC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Chemours Co (CC)'s fundamentals?

How many employees does Chemours Co (CC). have?

What is Chemours Co (CC) market cap?